NovoCure Limited

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-01 pm EST			5-day change	1st Jan Change
12.50 ^USD	+1.87%		+0.24%	-82.96%

Nov. 29	Transcript : NovoCure Limited Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 03:30 PM	CI
Nov. 28	Sector Update: Health Care Stocks Ease Tuesday Afternoon	MT

Presenter SpeechMaxwell Skor (Analysts)Okay. Great. Hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan...

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about NovoCure Limited

Transcript : NovoCure Limited Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 03:30 PM	Nov. 29	CI
Sector Update: Health Care Stocks Ease Tuesday Afternoon	Nov. 28	MT
Sector Update: Health Care	Nov. 28	MT
NovoCure to Cut Workforce by 13% in Restructuring Plan	Nov. 28	MT
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability	Nov. 28	CI
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	Oct. 26	MT
Transcript : NovoCure Limited, Q3 2023 Earnings Call, Oct 26, 2023	Oct. 26	CI
Earnings Flash (NVCR) NOVOCURE Reports Q3 Revenue $127.3M, vs. Street Est of $128.8M	Oct. 26	MT
NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 26	CI
NovoCure to Establish Tumor Treating Fields Research Program With Stanford University	Oct. 12	MT
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program	Oct. 12	CI
NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index	Sep. 18	CI
Transcript : NovoCure Limited Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 08:10 AM	Sep. 13	CI
Transcript : NovoCure Limited Presents at Wells Fargo Securities Healthcare Conference 2023, Sep-07-2023 12:45 PM	Sep. 07	CI
Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies	Aug. 29	CI
Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	Aug. 29	MT
Sector Update: Health Care Stocks Steady Late Afternoon	Aug. 28	MT
Sector Update: Health Care	Aug. 28	MT
Top Midday Decliners	Aug. 28	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	Aug. 28	MT
HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	Aug. 28	MT
Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	Aug. 28	MT
Sector Update: Health Care Stocks Mixed Premarket Monday	Aug. 28	MT
Beijing's Economic Stimulus Measures Lift US Equity Futures Pre-Bell	Aug. 28	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	Aug. 28	MT

NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company's key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-02-21 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for NovoCure Limited

Trading Rating :

Investor Rating :

ESG Refinitiv :

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.50USD

Average target price

26.14USD

Spread / Average Target

+109.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
NOVOCURE LIMITED	-82.96%	1 336 M $
PENUMBRA, INC.	+2.38%	8 790 M $
SHOCKWAVE MEDICAL, INC.	-11.39%	6 723 M $
GETINGE AB	+4.81%	5 947 M $
ASAHI INTECC CO., LTD.	+27.75%	5 223 M $
MASIMO CORPORATION	-34.63%	5 110 M $
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+6.06%	4 684 M $
INARI MEDICAL, INC.	-3.71%	3 525 M $
APT MEDICAL INC.	+23.06%	3 521 M $
ANDON HEALTH CO., LTD.	-27.16%	2 437 M $